Cargando…

Repurposing glucocorticoids as adjuvant reagents for immune checkpoint inhibitors in solid cancers

Detalles Bibliográficos
Autor principal:	Yu, Yingyan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Compuscript 2021
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8610151/ https://www.ncbi.nlm.nih.gov/pubmed/34697935 http://dx.doi.org/10.20892/j.issn.2095-3941.2021.0491

Ejemplares similares

Repurposing drugs for solid tumor treatment: focus on immune checkpoint inhibitors
por: Liu, Qingxu, et al.
Publicado: (2023)

Drug Repurposing to Circumvent Immune Checkpoint Inhibitor Resistance in Cancer Immunotherapy
por: To, Kenneth K. W., et al.
Publicado: (2023)

Immune checkpoint inhibitors in penile cancer
por: Buonerba, Carlo, et al.
Publicado: (2021)

Inhibiting the inhibitors: Checkpoints blockade in solid tumors
por: Mavilio, Domenico, et al.
Publicado: (2013)

Cardiotoxicity Associated with Immune Checkpoint Inhibitors
por: Minegishi, Shintaro, et al.
Publicado: (2023)

Adjuvant and neoadjuvant use of immune checkpoint inhibitors in NSCLC
por: Walia, Anushka, et al.
Publicado: (2023)

Unlocking the Potential of Biomarkers for Immune Checkpoint Inhibitors in Cancer Therapy
por: Dal Collo, Giada, et al.
Publicado: (2023)

Immune checkpoint inhibitors in renal cell carcinoma
por: Ross, Kirsty, et al.
Publicado: (2017)

Advanced Research on Immune Checkpoint Inhibitor Therapy
por: Imai, Hisao, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors for Solid Tumors in the Adjuvant Setting: Current Progress, Future Directions, and Role in Transplant Oncology
por: Abboud, Karen, et al.
Publicado: (2023)

Ibrutinib repurposing: from B-cell malignancies to solid tumors
por: Massó-Vallés, Daniel, et al.
Publicado: (2016)

The effects of glucocorticoids and immunosuppressants on cancer outcomes in checkpoint inhibitor therapy
por: Bruera, Sebastian, et al.
Publicado: (2022)

Immune checkpoint inhibitors: here to stay
por: Carvalho, Filomena Marino, et al.
Publicado: (2023)

Two Types of Immune Checkpoint Inhibitor-related Pancreatitis
por: Ichiki, Tomoko, et al.
Publicado: (2021)

The neurotoxic effects of immune checkpoint inhibitor therapy for melanoma
por: Spain, Lavinia, et al.
Publicado: (2019)

ICU admission for solid cancer patients treated with immune checkpoint inhibitors
por: Toffart, Anne-Claire, et al.
Publicado: (2023)

Evolving cardiac biomarkers for immune checkpoint inhibitor related myocarditis in cancer patients
por: Talukder, Suprateeka, et al.
Publicado: (2023)

Biomarkers for immune checkpoint inhibitors in colorectal cancer: recent advances and future perspectives
por: Yang, Changjiang, et al.
Publicado: (2023)

Immune checkpoint inhibitor in liver cancer—unique regional differences
por: Obi, Shuntaro, et al.
Publicado: (2020)

Checkpoint Inhibitors in Checkmating Rare Cancers
por: Srinivas, Sujay, et al.
Publicado: (2021)

Equibalancing immune‐related adverse events and anticancer activity of immune checkpoint inhibitors
por: Seeruttun, Sharvesh Raj
Publicado: (2019)

Management of gastrointestinal adverse events induced by immune-checkpoint inhibitors
por: Wang, Zheng-Hang, et al.
Publicado: (2018)

Immune Checkpoint Inhibitors in Uro-Oncology: Urgent Call for Biomarkers
por: Pichler, Renate
Publicado: (2020)

Cancer vaccines: the importance of targeting oncogenic drivers and the utility of combinations with immune checkpoint inhibitors
por: Crosby, Erika J., et al.
Publicado: (2021)

Immune checkpoint inhibitors in lung cancer: the holy grail has not yet been found…
por: Thungappa, Satheesh, et al.
Publicado: (2017)

Re-administration of immune checkpoint inhibitors for patients with non-small cell lung cancer
por: Hakozaki, Taiki
Publicado: (2022)

Immune checkpoint inhibitors for patients with gene-rearranged non-small cell lung cancer
por: Uehara, Yuji, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors in Cancer Therapy—How Can We Improve Clinical Benefits?
por: Baxevanis, Constantin N.
Publicado: (2023)

Repurposing Tecfidera for cancer
por: Booth, Laurence, et al.
Publicado: (2016)

Infectious complications of immune checkpoint inhibitors in solid organ malignancies
por: Ross, Justine Abella, et al.
Publicado: (2021)

Increasing cure rates of solid tumors by immune checkpoint inhibitors
por: Ma, Weijie, et al.
Publicado: (2023)

Glucocorticoids are double-edged sword in the treatment of COVID-19 and cancers
por: Yang, Ruixin, et al.
Publicado: (2021)

Drug Repurposing to Enhance Antitumor Response to PD-1/PD-L1 Immune Checkpoint Inhibitors
por: Thuru, Xavier, et al.
Publicado: (2022)

Assessment of soluble immune mediators as potential biomarkers during immune checkpoint inhibitor therapy
por: Matsuo, Norikazu, et al.
Publicado: (2019)

Drug Repurposing to Treat Glucocorticoid Resistance in Asthma
por: Wang, Alberta L., et al.
Publicado: (2021)

Immune Thrombocytopenia Induced by Immune Checkpoint Inhibitors in Solid Cancer: Case Report and Literature Review
por: Liu, Xiaolin, et al.
Publicado: (2020)

The ascent of immune checkpoint inhibitors: is the understudy ready for a leading role?
por: Cummings, Amy L., et al.
Publicado: (2017)

A Lack of Biomarkers for Cardiac Complications of Immune Checkpoint Inhibitor Therapy
por: Li, Siqi, et al.
Publicado: (2020)

Checkpoint inhibitors in gastrointestinal cancers: Expectations and reality
por: Kourie, Hampig Raphael, et al.
Publicado: (2017)

Do checkpoint inhibitors compromise the cancer patients’ immunity and increase the vulnerability to COVID-19 infection?
por: Kattan, Joseph, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_v11p8ibar5k34pqugb8la1tlaj